Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare neuroendocrine diseases. The company's mission is to transform the lives of these patients by rapidly advancing care and precision medicines that address the root cause of their conditions, aiming for a future where they can live their fullest lives with optimal, stigma-free care. Headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals focuses its efforts on addressing significant unmet medical needs in this specialized field.

The company's primary product is IMCIVREE (setmelanotide) injection, a precision medicine designed to treat hyperphagia (insatiable hunger) and severe obesity resulting from rare melanocortin-4 receptor (MC4R) pathway diseases. IMCIVREE is approved for chronic weight management in adult and pediatric patients (6 years and older) with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiencies, Bardet-Biedl syndrome (BBS), and acquired hypothalamic obesity. Rhythm Pharmaceuticals also maintains a pipeline of investigational MC4R agonists, including RM-718 and bivamelagon, and is exploring preclinical small molecules for congenital hyperinsulinism. Additionally, the company supports patient identification and diagnosis through its "Uncovering Rare Obesity Program," which offers no-cost genetic testing.

Led by Chairman, President, and CEO David Meeker, M.D., Rhythm Pharmaceuticals continues to advance its clinical programs and market presence. Recent notable activities in June 2026 include multiple data presentations at ENDO 2026 for its MC4R agonists in acquired hypothalamic obesity, Bardet-Biedl syndrome, and Prader-Willi syndrome, as well as positive interim six-month data from a Phase 2 trial of setmelanotide in Prader-Willi Syndrome patients. The company also reported its Q1 2026 financial results, with IMCIVREE generating $60.1 million in global net product revenue, following its FDA approval for acquired hypothalamic obesity in March 2026.